259 related articles for article (PubMed ID: 33633313)
1. Siglec-6 is a target for chimeric antigen receptor T-cell treatment of chronic lymphocytic leukemia.
Kovalovsky D; Yoon JH; Cyr MG; Simon S; Voynova E; Rader C; Wiestner A; Alejo J; Pittaluga S; Gress RE
Leukemia; 2021 Sep; 35(9):2581-2591. PubMed ID: 33633313
[TBL] [Abstract][Full Text] [Related]
2. Siglec-6 is a novel target for CAR T-cell therapy in acute myeloid leukemia.
Jetani H; Navarro-Bailón A; Maucher M; Frenz S; Verbruggen C; Yeguas A; Vidriales MB; González M; Rial Saborido J; Kraus S; Mestermann K; Thomas S; Bonig H; Luu M; Monjezi R; Mougiakakos D; Sauer M; Einsele H; Hudecek M
Blood; 2021 Nov; 138(19):1830-1842. PubMed ID: 34289026
[TBL] [Abstract][Full Text] [Related]
3. Siglec-6 on Chronic Lymphocytic Leukemia Cells Is a Target for Post-Allogeneic Hematopoietic Stem Cell Transplantation Antibodies.
Chang J; Peng H; Shaffer BC; Baskar S; Wecken IC; Cyr MG; Martinez GJ; Soden J; Freeth J; Wiestner A; Rader C
Cancer Immunol Res; 2018 Sep; 6(9):1008-1013. PubMed ID: 29980538
[TBL] [Abstract][Full Text] [Related]
4. Chimeric antigen receptor T cells targeting Fc μ receptor selectively eliminate CLL cells while sparing healthy B cells.
Faitschuk E; Hombach AA; Frenzel LP; Wendtner CM; Abken H
Blood; 2016 Sep; 128(13):1711-22. PubMed ID: 27535994
[TBL] [Abstract][Full Text] [Related]
5. In vitro and in vivo model of a novel immunotherapy approach for chronic lymphocytic leukemia by anti-CD23 chimeric antigen receptor.
Giordano Attianese GM; Marin V; Hoyos V; Savoldo B; Pizzitola I; Tettamanti S; Agostoni V; Parma M; Ponzoni M; Bertilaccio MT; Ghia P; Biondi A; Dotti G; Biagi E
Blood; 2011 May; 117(18):4736-45. PubMed ID: 21406718
[TBL] [Abstract][Full Text] [Related]
6. Current State of CAR T-Cell Therapy in Chronic Lymphocytic Leukemia.
Mancikova V; Smida M
Int J Mol Sci; 2021 May; 22(11):. PubMed ID: 34073911
[TBL] [Abstract][Full Text] [Related]
7. A Novel Siglec-4 Derived Spacer Improves the Functionality of CAR T Cells Against Membrane-Proximal Epitopes.
Schäfer D; Henze J; Pfeifer R; Schleicher A; Brauner J; Mockel-Tenbrinck N; Barth C; Gudert D; Al Rawashdeh W; Johnston ICD; Hardt O
Front Immunol; 2020; 11():1704. PubMed ID: 32849600
[TBL] [Abstract][Full Text] [Related]
8. Ibrutinib for improved chimeric antigen receptor T-cell production for chronic lymphocytic leukemia patients.
Fan F; Yoo HJ; Stock S; Wang L; Liu Y; Schubert ML; Wang S; Neuber B; Hückelhoven-Krauss A; Gern U; Schmitt A; Müller-Tidow C; Dreger P; Schmitt M; Sellner L
Int J Cancer; 2021 Jan; 148(2):419-428. PubMed ID: 32683672
[TBL] [Abstract][Full Text] [Related]
9. Reducing Hinge Flexibility of CAR-T Cells Prolongs Survival
Zhang A; Sun Y; Du J; Dong Y; Pang H; Ma L; Si S; Zhang Z; He M; Yue Y; Zhang X; Zhao W; Pi J; Chang M; Wang Q; Zhang Y
Front Immunol; 2021; 12():724211. PubMed ID: 34675920
[TBL] [Abstract][Full Text] [Related]
10. CD19 Chimeric Antigen Receptor T Cells From Patients With Chronic Lymphocytic Leukemia Display an Elevated IFN-γ Production Profile.
Magalhaes I; Kalland I; Kochenderfer JN; Österborg A; Uhlin M; Mattsson J
J Immunother; 2018; 41(2):73-83. PubMed ID: 29315094
[TBL] [Abstract][Full Text] [Related]
11. Safety and tolerability of conditioning chemotherapy followed by CD19-targeted CAR T cells for relapsed/refractory CLL.
Geyer MB; Rivière I; Sénéchal B; Wang X; Wang Y; Purdon TJ; Hsu M; Devlin SM; Palomba ML; Halton E; Bernal Y; van Leeuwen DG; Sadelain M; Park JH; Brentjens RJ
JCI Insight; 2019 Apr; 5(9):. PubMed ID: 30938714
[TBL] [Abstract][Full Text] [Related]
12. The severe cytokine release syndrome in phase I trials of CD19-CAR-T cell therapy: a systematic review.
Jin Z; Xiang R; Qing K; Li X; Zhang Y; Wang L; Zhu H; Mao Y; Xu Z; Li J
Ann Hematol; 2018 Aug; 97(8):1327-1335. PubMed ID: 29766234
[TBL] [Abstract][Full Text] [Related]
13. Chimeric antigen receptor-modified T cell therapy in chronic lymphocytic leukemia.
Zou Y; Xu W; Li J
J Hematol Oncol; 2018 Nov; 11(1):130. PubMed ID: 30458878
[TBL] [Abstract][Full Text] [Related]
14. Function of Novel Anti-CD19 Chimeric Antigen Receptors with Human Variable Regions Is Affected by Hinge and Transmembrane Domains.
Alabanza L; Pegues M; Geldres C; Shi V; Wiltzius JJW; Sievers SA; Yang S; Kochenderfer JN
Mol Ther; 2017 Nov; 25(11):2452-2465. PubMed ID: 28807568
[TBL] [Abstract][Full Text] [Related]
15. Homogeneously high expression of CD32b makes it a potential target for CAR-T therapy for chronic lymphocytic leukemia.
Wang G; Sun X; Zuo S; Li C; Niu Q; Xia Y; Meng Y; Liu M; Fang Z; Yang X; Jiang Y; Wang S; Cui H; Huang H; Jiang E; Zhou D; Deng Q; Pan J; Feng X
J Hematol Oncol; 2021 Sep; 14(1):149. PubMed ID: 34530888
[TBL] [Abstract][Full Text] [Related]
16. Transforming CLL management with immunotherapy: Investigating the potential of CAR T-cells and bispecific antibodies.
Borogovac A; Siddiqi T
Semin Hematol; 2024 Apr; 61(2):119-130. PubMed ID: 38290860
[TBL] [Abstract][Full Text] [Related]
17. Accelerating chimeric antigen receptor therapy in chronic lymphocytic leukemia: The development and challenges of chimeric antigen receptor T-cell therapy for chronic lymphocytic leukemia.
Bair SM; Porter DL
Am J Hematol; 2019 May; 94(S1):S10-S17. PubMed ID: 30861173
[TBL] [Abstract][Full Text] [Related]
18. Modulating TNFα activity allows transgenic IL15-Expressing CLL-1 CAR T cells to safely eliminate acute myeloid leukemia.
Ataca Atilla P; McKenna MK; Tashiro H; Srinivasan M; Mo F; Watanabe N; Simons BW; McLean Stevens A; Redell MS; Heslop HE; Mamonkin M; Brenner MK; Atilla E
J Immunother Cancer; 2020 Sep; 8(2):. PubMed ID: 32938629
[TBL] [Abstract][Full Text] [Related]
19. Chimeric Antigen Receptor T Cells Targeting CD79b Show Efficacy in Lymphoma with or without Cotargeting CD19.
Ormhøj M; Scarfò I; Cabral ML; Bailey SR; Lorrey SJ; Bouffard AA; Castano AP; Larson RC; Riley LS; Schmidts A; Choi BD; Andersen RS; Cédile O; Nyvold CG; Christensen JH; Gjerstorff MF; Ditzel HJ; Weinstock DM; Barington T; Frigault MJ; Maus MV
Clin Cancer Res; 2019 Dec; 25(23):7046-7057. PubMed ID: 31439577
[TBL] [Abstract][Full Text] [Related]
20. Gamma-Delta CAR-T Cells Show CAR-Directed and Independent Activity Against Leukemia.
Rozenbaum M; Meir A; Aharony Y; Itzhaki O; Schachter J; Bank I; Jacoby E; Besser MJ
Front Immunol; 2020; 11():1347. PubMed ID: 32714329
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]